Laboratory Solutions to Support Global COVID-19 Clinical Trials

As a leading laboratory services organization for trials across the globe, Q2 Solutions is proud to partner in support of upcoming COVID-19 clinical trials.

Our global network of state-of-the-art laboratories offer Central Laboratories located in Valencia (CA, United States), Edinburgh (United Kingdom), Mumbai (India), Singapore, Beijing (China) and Tokyo (Japan) with partner laboratories in South America and South Africa. Our Centers of Excellence for Vaccines, Genomics and Bioanalytical/ADME are strategically located to offer worldwide testing solutions.

We provide cutting-edge technologies, including detection of SARSCoV-2 virus and antibodies; vaccine neutralization testing; immunologic profiling (flow cytometry and cytokine detection); immunogenicity analysis; bioanalytic techniques for pharmacodynamics and pharmacokinetics and human and SARS-CoV-2 virus genomic analysis. Q2 Solutions has the global capacity and high-quality infrastructure to support your COVID-19 clinical trials.

SARS-CoV-2/COVID-19 testing portfolio

Global regulatory readiness for COVID-19 sample handling and testing. Representative laboratory services offered:

SARS-CoV-2 PCR tests
  • Qualitative to support patient enrollment (inclusion/exclusion)
  • Quantitative to support efficacy endpoint
Serological antibody tests
  • Qualitative total immunoglobulin (Ig) to support patient enrollment (inclusion/exclusion)
  • Qualitative and quantitative IgM and IgG to identify early versus late infection
  • Quantitative IgM and IgG titers to assess drug off-target effects
Vaccine assays
  • Immunogenicity: Spike and nucleocapsid antigen specific quantitative ELISA antibody measurement
  • Developing a neutralization assay through a collaboration with University of Texas Medical Branch
  • Partnership with the Coalition for Epidemic Preparedness Innovation (CEPI) to harmonize evaluation of multiple COVID-19 vaccine candidates
  • SARS-CoV-2 specific T-cell response assessment
  • SARS-CoV-2 surrogate neutralization assay, used under license from the Albert Einstein College of Medicine
Cytokine panels
  • Detection of cytokines including IL-1β, IL-2, IL-4, IL-6, IL-7, IL-10, IFN-γ, GCSF, IP-10, MCP-1, MIP-1α, TNF-α to monitor cytokine storm
Comprehensive portfolio of genomic assays
  • SARS-CoV-2 complete viral genome sequencing by NGS
  • Host transcriptomic analysis by RNA sequencing and targeted analyses
  • Host genomic analysis by whole exome sequencing and targeted genotyping
  • Host metagenomic analysis by 16S RNA metagenomic sequencing
  • DNA and RNA sequencing
  • Gene expression panels for inflammatory and immune response monitoring
Comprehensive flow cytometry panels utilizing cutting-edge next-generation instruments
  • T cells: CD3+CD4+CD8-/CD3+CD4-CD8+ ratio, CD3+CD4+IFN-γ+, CD3+CD8+CD38+HLA-DR+, Th, Th1, Th2, Th17, T-Follicular helper, Treg naïve/memory and intracellular staining: IL-2, IL-4, IL-6, IL-17A, IFN-γ GM-CFS, Granulysin, Granzyme B, Perforin, and TNF-α
  • B cells: Plasmablasts, plasma cells – short-lived/long-lived, and memory B cells
  • Monocytes: Blood monocyte shift to inflammatory phenotype
  • Macrophages: Broncho-alveolar lavage
  • Monocyte-derived dendritic cell analysis
Conventional safety markers for prognostic evaluation
  • Chemistry: Ferritin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyper-sensitive troponin I, lactate dehydrogenase (LDH), C-reactive protein (CRP), procalcitonin, albumin
  • Hematology: WBC, neutrophils, lymphocytes and platelets counts
  • Disseminated intravascular coagulation (DIC): Prothrombin time (PT), partial thromboplastin time (aPTT), and D-dimer
Bioanalytical services
  • Large molecule PK, immunogenicity/anti-drug antibody ligand-binding assays
  • Small molecule PK and drug-drug interaction


Global laboratory footprint
We have a global delivery network of >3,000 employees in >12 countries.

Study delivery and logistics

  • Expedited study set-up
    Rapid set-up, flexibility and commitment to support COVID-19 studies
  • Global kit production and logistics capabilities
    Navigating change through robust supply chain infrastructure, flexible kitting solutions and agile logistics support
  • Near patient collection and local lab data management
    Supporting patients and sites with trial continuity solutions including home nurses and phlebotomists
  • Business continuity
    Proactive and coordinated approach in place to minimize impact on our staff and business operations – Read message from our CEO

Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health.